Incannex Healthcare Ltd, a pharmaceutical drugs developer, has filed Form S-1 Registration Statement on August 17, 2021 with the U.S. Securities and Exchange Commission to raise up to $27 million IPO. Pricing terms are yet to announce.
The company creates premier ethical pharmaceutical drugs and therapies for patients with unmet medical needs, in all instances fulfilling regulatory requirements of the Food and Drug Administration (“FDA”) and other relevant regulatory agencies.
The Docklands, Australia-based company was founded in 2001 and booked $2 million in revenue for the 12 months ended December 31, 2020. It plans to list on the Nasdaq Capital Market under the symbol “IXHL.” Roth Capital is the underwriter of the IPO.
The company engages Latham & Watkins LLP as US Securities Counsel, and KPMG AG as Independent Auditor.
#ipo #nasdaq #IncannexHealthcare #drugs
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]